When did NOVARTIS AG-SPONSORED ADR (NVS) report earnings last quarter?
NOVARTIS AG-SPONSORED ADR (NVS) last reported earnings on 2/4/2026.
NYSE:NVS • US66987V1098
Past quarterly earnings results for NOVARTIS AG-SPONSORED ADR (NVS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 2.04 | 2.04 | -0.17% | 2.53% | 13.336B | 14.022B | -4.89% | 1.39% |
| Q3 2025 | 2.26 | 2.31 | -2.10% | 9.22% | 13.909B | 14.312B | -2.82% | 8.47% |
| Q2 2025 | 2.43 | 2.42 | 0.61% | 22.84% | 14.054B | 14.465B | -2.84% | 12.32% |
| Q1 2025 | 2.29 | 2.15 | 6.59% | 26.67% | 13.233B | 13.384B | -1.13% | 11.87% |
| Q4 2024 | 1.99 | 1.88 | 6.06% | 29.41% | 13.153B | 13.051B | 0.78% | 15.14% |
| Q3 2024 | 2.07 | 2.00 | 3.78% | 12.57% | 12.823B | 12.994B | -1.32% | 8.84% |
| Q2 2024 | 1.98 | 1.92 | 3.24% | 7.65% | 12.512B | 12.61B | -0.78% | -8.15% |
| Q1 2024 | 1.81 | 1.72 | 5.40% | 5.26% | 11.829B | 11.709B | 1.02% | 7.08% |
| Q4 2023 | 1.54 | 1.66 | -7.44% | 0.66% | 11.423B | 11.996B | -4.78% | 4.99% |
| Q3 2023 | 1.84 | 1.77 | 3.88% | 15.82% | 11.782B | 12.001B | -1.82% | 9.26% |
| Q2 2023 | 1.84 | 1.74 | 5.73% | 17.31% | 13.622B | 13.518B | 0.77% | -37.26% |
| Q1 2023 | 1.72 | 1.57 | 9.32% | 17.12% | 11.047B | 12.877B | -14.21% | -13.79% |
| Q4 2022 | 1.53 | 1.44 | 6.28% | 8.57% | 10.88B | 13.285B | -18.10% | 135.55% |
| Q3 2022 | 1.59 | 1.59 | -0.02% | -7.60% | 10.783B | 13.106B | -17.72% | -19.33% |
| Q2 2022 | 1.57 | 1.54 | 2.08% | -6.02% | 21.712B | 13.109B | 65.63% | 63.32% |
| Q1 2022 | 1.47 | 1.48 | -0.62% | -3.95% | 12.814B | 12.942B | -0.99% | 0.95% |
| Q4 2021 | 1.41 | 1.45 | -3.12% | 4.48% | 4.619B | 13.616B | -66.08% | -64.55% |
| Q3 2021 | 1.72 | 1.69 | 1.93% | 12.50% | 13.367B | 13.285B | 0.62% | 6.61% |
| Q2 2021 | 1.67 | 1.58 | 5.67% | 22.06% | 13.294B | 12.773B | 4.08% | 14.39% |
| Q1 2021 | 1.53 | 1.60 | -4.32% | -2.56% | 12.694B | 12.771B | -0.60% | -0.11% |
| Q4 2020 | 1.35 | 1.41 | -4.21% | - | 13.03B | 13.147B | -0.89% | - |
| Q3 2020 | 1.53 | 1.49 | 2.60% | - | 12.538B | 12.818B | -2.18% | - |
| Q2 2020 | 1.37 | 1.36 | 0.78% | - | 11.622B | 12.13B | -4.19% | - |
| Q1 2020 | 1.57 | 1.43 | 9.89% | - | 12.708B | 12.249B | 3.75% | - |
Notes
NOVARTIS AG-SPONSORED ADR (NVS) last reported earnings on 2/4/2026.
NOVARTIS AG-SPONSORED ADR (NVS) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NOVARTIS AG-SPONSORED ADR (NVS) has beaten EPS estimates in 2 out of 4 releases.